IndyGeneUS AI and the Blockchain-Secured Genomic Data Marketplace IndyGeneUS AI, which is harnessing the power of data mining and artificial intelligence to expedite the development and manufacturing of targeted therapeutics, [….]
Jonny’s back! Despite the continuation of COVID -19 through 2021, 2021 was a spectacular year for venture fundraising. Investment in every healthcare sector set records, and most experienced record IPO [….]
We have been covering the biomanufacturing workforce at length this year because it remains one of the most important topics for companies in today’s near full-employment job market.
Emergent BioSolutions Inc. (NYSE:EBS) today announced that two batches of COVID-19 vaccine manufactured by Emergent BioSolutions at its Baltimore Bayview facility were determined to be suitable for use by the U.S. Food & Drug Administration (FDA) and have been authorized as part of Johnson & Johnson’s Emergency Use Authorization (EUA).
Set on the historic Walter Reed Army Medical Center, the Children’s National Research & Innovation Campus will be a one-of-kind innovation hub. The nearly 12-acre campus will house leading entrepreneurs, [….]
Novavax trials highlight Maryland’s COVID-fighting complex When Novavax Inc. received $1.6 billion last year from the federal government to speed up testing and production of a coronavirus vaccine, some observers [….]
For entrepreneurs and early stage companies, raising capital can be challenging. For female entrepreneurs it can be even more challenging as they can experience gender bias in their efforts to [….]
Expanding the mechanisms for administering therapeutics and vaccines may have the potential to disrupt the status quo and improve availability and accessibility of therapeutic and preventive treatments. This session will [….]
Emergent BioSolutions’ contract development and manufacturing (CDMO) business is playing a crucial role in supporting the battle against COVID-19. The company has contracted with multiple vaccine makers, including AstraZeneca and Johnson & Johnson, to manufacture the preventative medications.
Rachel is the Director of the BARDA Alliance for Johnson & Johnson Innovation, based at JLABS @ Washington, DC. In this role, she is responsible for managing the BLUE KNIGHT™ collaboration between Johnson & Johnson Innovation – JLABS (JLABS) and the Biomedical Advanced Research and Development Authority (BARDA). BLUE KNIGHT™ focuses on addressing public-health threats and emerging infectious diseases by supporting companies with emerging science and technology solutions that aim to improve health security and responses.
